on Wednesday, December 7, 2011
Memorial Sloan Kettering medical oncologist Clifford A. Hudis has been elected President of the American Society of Clinical Oncology, the world’s leading professional organization representing more than 30,000 physicians who care for people with cancer.
Memorial Sloan Kettering medical oncologist Clifford A. Hudis has been elected President of the American Society of Clinical Oncology (ASCO), the world’s leading professional organization representing more than 30,000 physicians who care for people with cancer. A renowned leader in practice-changing translational research and clinical care, he will be introduced as President-Elect during ASCO’s 48th Annual Meeting in June 2012 and will serve for a one-year term as President beginning in June 2013.
As ASCO’s President, Dr. Hudis will work collaboratively with its membership to further the society’s goals of improving all aspects of cancer care, including access, effectiveness, and affordability.
Dr. Hudis, Chief of the Breast Cancer Medicine Service at Memorial Sloan Kettering, has an active medical practice that is devoted solely to the treatment of patients with breast cancer, and he has a particular interest in applying emerging technology to both clinical and research settings.
“We are delighted and proud that Cliff Hudis has been elected President of ASCO,” says Memorial Sloan Kettering President Craig B. Thompson. “Cliff has made MSKCC his professional home since joining the institution as a fellow in 1988. He is an outstanding and dedicated breast cancer clinician, researcher, and teacher, and has been a national leader in the development of new and more-effective treatments for breast cancer. His investigative acumen has improved the care of patients with all stages of the disease, placing him among the most influential physician-scientists in the field. ASCO is indeed fortunate to have him.”
Dr. Hudis’s research is focused on prevention of the disease, prevention of recurrence after surgery, and treatment of recurrences. Specifically, he is involved in clinical and translational studies that aim to develop better hormone therapies, improved chemotherapy drugs, more-effective and less-toxic methods of drug delivery, and newer highly specific agents.
This work is conducted both at Memorial Sloan Kettering and also through his role as the Breast Committee Co-Chair of the Cancer and Leukemia Group B, a national clinical research group sponsored by the National Cancer Institute.
Board certified in internal medicine and medical oncology, Dr. Hudis has played a leadership role in many clinical trials investigating new treatments and has published numerous papers in a wide range of prestigious medical journals.
Dr. Hudis obtained his medical degree from the Medical College of Pennsylvania, where he completed his internship and residency, and was a fellow in medical oncology and hematology at Memorial Sloan Kettering.
Since joining ASCO in 1991, Dr. Hudis has demonstrated his dedication to the organization through his active service and leadership. Most recently, he served as Treasurer of the ASCO Board of Directors and is currently an Associate Editor for the Journal of Clinical Oncology, ASCO’s flagship publication.
Additionally, Dr. Hudis is a Co-Chair of the Breast Committee of the Alliance for Clinical Trials in Oncology, a member of the Steering Committee of the Translational Breast Cancer Research Consortium, and Chairman of the Scientific Advisory Committee of the Breast Cancer Research Foundation. He is also a Fellow of the American College of Physicians.